Notice2022-19897
Foreign-Trade Zone (FTZ) 153-San Diego, California, Notification of Proposed Production Activity, Ajinomoto Bio-Pharma Services (Pharmaceutical Products), San Diego, California
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
September 15, 2022
Issuing agencies
Commerce DepartmentForeign-Trade Zones Board
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 178 (Thursday, September 15, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 178 (Thursday, September 15, 2022)]
[Notices]
[Page 56626]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-19897]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B-42-2022]
Foreign-Trade Zone (FTZ) 153--San Diego, California, Notification
of Proposed Production Activity, Ajinomoto Bio-Pharma Services
(Pharmaceutical Products), San Diego, California
The City of San Diego, grantee of FTZ 153, submitted a notification
of proposed production activity to the FTZ Board (the Board) on behalf
of Ajinomoto Bio-Pharma Services, located in San Diego, California
under FTZ 153. The notification conforming to the requirements of the
Board's regulations (15 CFR 400.22) was received on September 7, 2022.
Pursuant to 15 CFR 400.14(b), FTZ production activity would be
limited to the specific foreign-status material(s)/component(s) and
specific finished product(s) described in the submitted notification
(summarized below) and subsequently authorized by the Board. The
benefits that may stem from conducting production activity under FTZ
procedures are explained in the background section of the Board's
website--accessible via <a href="http://www.trade.gov/ftz">www.trade.gov/ftz</a>.
The proposed finished product is yusimry--(active pharmaceutical
ingredient (API) substance and packaging into measured doses in vials
and/or syringes) (duty-free).
The proposed foreign-status material and component is yusimry API
substance (duty-free).
Public comment is invited from interested parties. Submissions
shall be addressed to the Board's Executive Secretary and sent to:
<a href="/cdn-cgi/l/email-protection#0c6a78764c787e6d6869226b637a"><span class="__cf_email__" data-cfemail="7c1a08063c080e1d1819521b130a">[email protected]</span></a>. The closing period for their receipt is October 25,
2022.
A copy of the notification will be available for public inspection
in the ``Online FTZ Information System'' section of the Board's
website.
For further information, contact Christopher Wedderburn at
<a href="/cdn-cgi/l/email-protection#8ecde6fce7fda0d9ebeaeaebfcecfbfce0cefafcefeaeba0e9e1f8"><span class="__cf_email__" data-cfemail="ffbc978d968cd1a89a9b9b9a8d9d8a8d91bf8b8d9e9b9ad1989089">[email protected]</span></a>.
Dated: September 9, 2022.
Elizabeth Whiteman,
Acting Executive Secretary.
[FR Doc. 2022-19897 Filed 9-14-22; 8:45 am]
BILLING CODE 3510-DS-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on September 15, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.